Alnylam Pharmaceuticals (ALNY) Hits New 1-Year High on Analyst Upgrade
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) hit a new 52-week high during trading on Tuesday after Credit Suisse Group raised their price target on the stock from $151.00 to $154.00. Credit Suisse Group currently has an outperform rating on the stock. Alnylam Pharmaceuticals traded as high as $148.78 and last traded at $148.69, with a volume of 1166776 shares changing hands. The stock had previously closed at $142.04.
A number of other brokerages have also recently commented on ALNY. Leerink Swann raised their price objective on Alnylam Pharmaceuticals from $132.00 to $135.00 and gave the company a “market perform” rating in a research note on Thursday, January 25th. Piper Jaffray Companies reissued a “buy” rating and issued a $182.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Sunday, January 7th. B. Riley reissued a “buy” rating and issued a $220.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, December 11th. BidaskClub cut Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Finally, Chardan Capital reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Friday, January 19th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. Alnylam Pharmaceuticals has an average rating of “Buy” and a consensus target price of $126.89.
In other Alnylam Pharmaceuticals news, VP Michael Mason sold 36,745 shares of the business’s stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $131.59, for a total value of $4,835,274.55. Following the sale, the vice president now directly owns 6,352 shares in the company, valued at $835,859.68. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Laurie Keating sold 6,249 shares of the business’s stock in a transaction on Wednesday, December 20th. The shares were sold at an average price of $121.20, for a total value of $757,378.80. Following the completion of the sale, the senior vice president now owns 17,749 shares in the company, valued at $2,151,178.80. The disclosure for this sale can be found here. 4.30% of the stock is currently owned by insiders.
The company has a debt-to-equity ratio of 0.02, a current ratio of 12.23 and a quick ratio of 12.23. The company has a market cap of $13,284.42, a PE ratio of -27.52 and a beta of 2.67.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 8th. The biopharmaceutical company reported ($1.48) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.38) by ($0.10). Alnylam Pharmaceuticals had a negative return on equity of 41.08% and a negative net margin of 545.95%. The business had revenue of $37.90 million for the quarter, compared to analysts’ expectations of $19.31 million. During the same quarter in the previous year, the firm earned ($1.32) earnings per share. Alnylam Pharmaceuticals’s quarterly revenue was up 116.6% compared to the same quarter last year. sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.88 earnings per share for the current fiscal year.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.